



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit	: 1642	Customer No.:	035811
Examiner	: Brandon J. Fetterolf		
Serial No.	: 10/740,266		
Filed	: December 18, 2003		
Inventors	: Christian Auclair	Docket No.:	1417-03
	: Valérie Amsellem		
	: Martial Hervy	Confirmation No.:	2270
	: Frédéric Subra		
Title	: PHARMACEUTICAL COMPOSITION FOR THE		
	: DIAGNOSIS, PREVENTION OR TREATMENT		
	: OF A TUMORAL PATHOLOGY COMPRISING		
	: AN AGENT MODULATING THE		
	: POLYMERIZATION STATE OF ACTIN		

DECLARATION OF PROFESSOR MICHEL JEAN ROBERT PERRICAUDET

Mail Stop AF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Michel Jean Robert Perricaudet, declare that I reside at 31 rue de Chartres, 28320 Ecrosnes, France.

I received an M.S. in Physical Chemistry from the University of Paris VI in 1972 and a doctorate in Physical Chemistry from the same University in 1973. I then engaged in a new doctoral training at the Institut Pasteur from 1973 through 1980. I received a Ph.D in 1980 from University of Paris VII and conducted further postdoctoral work at SUNY Stony-Brook University from 1980-1981. Since 1982 and extending through today, I have been a director of research at CNRS in the following capacities: a sub-group of Unit ER 272, Unit UA 1301, Unit UMR 1582 and Unit UMR 8121. I have received five awards from Val de Marne, La Ligue, Nationale Contre le Cancer, the French Académie Nationale de Médecine and the French Académie Nationale des Sciences and have further been a research consultant for Institut Mérieux, Transgène-Mérieux and Rhône-Poulenc Rorer. I am also on the editorial board of

PHIL13831253.1

Human Gene Therapy, Gene Therapy, Molecular Therapy and The Journal of Gene Medicine.


I have read and understand the contents of the above-identified application. I have also read the claims of this application and understand that they have been rejected because they contain subject matter that was not described in the Specification in such a way to enable one skilled in the art to make and/or use that claimed subject matter.

As one skilled in the gene therapy art, I believe that the disclosure of the above-identified application is more than sufficient to enable one skilled in the art to practice the subject matter of the claims. This is particularly true given the experimental work done by the inventors as described in the Specification.

I also believe that this is evidenced by the experimental work performed by Céline Bouquet. That work was based on a reading and understanding of the subject matter set forth in the above-identified application. Therefore, I believe that the Specification sufficiently describes the claimed subject matter for one skilled in the art to substantially duplicate the claimed subject matter without requiring undue experimentation, but only normal, routine experimentation well known to those in the gene therapy art.

The undersigned declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and thus such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: June 20th 2007



Michel Jean Robert Perricaudet